| Matt Eyles, president and CEO of America’s Health Insurance Plans (AHIP), issued this statement following the U.S. Patent and Trademark Office (USPTO) final rule, changing the claim construction standard applied during inter partes review (IPR), post-grant review (PGR), and the transitional program for covered business method patents (CBM) proceedings: "Every single American should be able to afford the medications they need. Drug prices are out-of-control, and we must advance policies that increase choice, competition and end this anti-generic patent gaming pursued by Big Pharma." ... |